Editas Medicine Restructures, Cuts 65% of Workforce to Focus on In Vivo Gene Editing
Editas Medicine announced it will lay off 65% of its workforce, approximately 180 employees, as it discontinues its lead gene-editing program for sickle cell disease. This decision comes amid a challenging financial period for the gene-editing industry, with declining valuations and widespread layoffs. Despite its promising start as a CRISPR pioneer, Editas has faced execution challenges and significant turnover, leading to this strategic shift.